期刊文献+

武汉城区致病性酵母菌的药物敏感性 被引量:4

An Evaluation of the Susceptibility of Yeast to Fluconazole and Itraconazole in Wuhan Urban
下载PDF
导出
摘要 目的:研究武汉城区致病性酵母菌对氟康唑、伊曲康唑的体外药物敏感性。方法:酵母菌收集自武汉市3家大型综合性医院住院患者提供的标本。分别采用美国国家临床实验室标准化委员会的M38A方案的纸片扩散法和M27A2方案的微量稀释法对氟康唑和伊曲康唑进行体外药物敏感实验,分别测定抑菌圈直径和最小抑菌浓度(MIC),统计分离菌株的构成比以及不同种菌株对氟康唑、伊曲康唑的敏感率。结果:共分离出186株菌,白色念珠菌占67.2%,其次为热带念株菌15.6%,光滑念珠菌15.1%,克柔念珠菌1.6%,葡萄牙念珠菌0.54%。111株实验菌株对氟康唑的总敏感率为87.3%,其中白色念珠菌为96.1%,光滑念珠菌为52.9%;对伊曲康唑总敏感率为78.4%,其中白色念珠菌为84.6%,光滑念珠菌为41.2%。结论:武汉城区致病性酵母菌以白色念珠菌分离率最高,其对氟康唑、伊曲康唑有较高的敏感性,光滑念珠菌对两种药物的敏感性明显低于白色念珠菌。实验室重视对菌种的鉴定,积极开展体外药物敏感实验有利于指导临床治疗。 Objective: To investigate the susceptibility of yeast which isolated form the three large hospitals in Wuhan from October, 2003 to April, 2004 to fluconazole and itraconazole. Methods: The susceptibility testing was performed using a yeast disk diffusion method and microdillution method respectively. Both of them were approved by the National Committee for Clinical Laboratory Standards (NCCLS). Results: 186 strains of yeast were isolated, of which the Candida albicans accounted for 67.2% of all the isolates; C. tropicalis, C. glabrata, C. krusei and C. portugal accounted for 15.6%, 15.1% ,1.6% and 0.54% respectively. The total susceptibility rates of the 111 isolates to fluconazole and itraconazole were 87.3% and 78.4% respectively, while the susceptibility rates of Candida albicans to fluconazole and itraconazole were 96.1% and 84.6%, the susceptibility rates of C. glabrata to fluconazole and itraconazole were 52.9% and 41.2%. Conclusion: Candida albicans were the most frequent organisms isolated in Wuhan urban. Fluconazole and itraconazole were quite effective to Candida albicans and C. tropicalis, but less effective to C .glabrata. The clinical laboratory should identify the isolates to species and do the microbial sensitivity tests. It will be more helpful for clinicians to treat the fungal infection.
出处 《武汉大学学报(医学版)》 CAS 2005年第3期383-386,共4页 Medical Journal of Wuhan University
关键词 抗真菌药 微生物敏感试验 酵母样真菌 Antifungal Agent Microbial Sensitivity Test Yeasts
  • 相关文献

参考文献8

  • 1Kao AS, Brandt ME, Pruitt WR, et al. The epidemiology of candidemia in two United States cities: result of a population-based active surveillance. Clin Infect Dis, 1999, 29:1 164.
  • 2National Committee for Clinical Laboratory Standards. Method for antifungal disk diffusion susceptibility testing of yeasts: proposed guideline. NCCLS, 2003,123:6.
  • 3National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts approved standard second edition. NCCLS, 2002,122:15.
  • 4Edmond MB, Wallace SE, Mcclish DK, et al. Nosocomial bloodstream infection in United States Hospitals: a three-year analysis. Clin Infect Dis, 1999,29:239.
  • 5徐英春,王澎,原英,谢秀丽,张月贤,刘娟,陈民钧.氟康唑和伏立康唑对酵母菌抗菌活性的研究[J].中国抗感染化疗杂志,2003,3(5):277-279. 被引量:23
  • 6Dimitrios PK, Rusell EL. Antifungal drug resistance of pathogenic fungi. The Lancet, 2002,359:1 135.
  • 7Mar Masiā Canuto, félix Gutiérrez Rodero. Antifungal drug resistance to azoles and polyenes. The Lancet Infection Diseases, 2002,2:550.
  • 8Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro correlation data foe fluconazole, itraconazole, and candida infections. Clin Infect Dis, 1997, 24:235.

二级参考文献9

  • 1Wenzel R, Brewer TF, Butzler JP,et al. Fungi, A guide to infection control in the hospital(2nd Edition),international society for infection diseases[M]. Boston,MA.USA, BC Decker Inc Hamilton. London, 2002, 157-159
  • 2National Committee for Clinical Laboratory Standards. Method for antifungal disk diffusion susceptibility testing of yeasts; proposed guideline[S]. NCCLS M44-P, 2003, 123: 6
  • 3Berke I, Tierno PM Jr. Comparison of efficacy and cost-effectiveness of BIOMIC video and Vitek antimicrobial susceptibility test systems for use in the clinical microbiology laboratory[J]. J Clinical Microbiology,1996, 34:1980-1984
  • 4Rangel-Frausto MS, Wiblin T, Blumberg HM,et al. National Epidemiology of Mycoses Survey. Variations in rates of Candida Bloodstream Infections due to candida species in Seven surgical ICUs and six Neonatal ICUs[J]. Clin Infect Dis 1999, 29:253-258
  • 5Edmond MB,Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States Hospitals: a three-year analysis[J]. Clin Infect Dis,1999, 29:239-244
  • 6Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States,1980-1990[J].J Infect Dis ,1993,167:1247-1251
  • 7Pfaller MA, Jones RN, Doern GV, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY program[J]. J Clin Microbiol ,1998, 36:1886-1889
  • 8Paterson PJ, McWhinney PH, Potter M, et al. The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients[J]. Br J Haemotol, 2001,112:175-180
  • 9Rogers TR. Antifungal drug resistance: does it matter?[J] International Journal of Infectious Diseases,2002,6(supp1):S47-S53

共引文献22

同被引文献22

  • 1刘华,周中华,喻华,颜英俊,王蓉,古义俞.260株念珠菌分离鉴定及耐药性分析[J].中华医院感染学杂志,2004,14(3):347-349. 被引量:49
  • 2黄进波,陈升豪,李佩芸,林少群.临床送检标本11442份病原真菌菌种分析[J].中国麻风皮肤病杂志,2005,21(3):190-192. 被引量:10
  • 3施金玲,蔡璇,孙端阳.酵母菌医院感染的危险因素与耐药性分析[J].医药导报,2006,25(1):68-70. 被引量:7
  • 4张淑芳,吴多荣,张冬霞.593株念珠菌医院感染分布和耐药现状分析[J].国际检验医学杂志,2006,27(5):467-468. 被引量:7
  • 5陈翠珠,徐英春,王澎,杨启文,谢秀丽,陈民钧.1557株酵母菌的鉴定及其药敏试验分析[J].中国真菌学杂志,2006,1(3):134-138. 被引量:25
  • 6Pfaller MA, Diekema D J, Rinaldi MG, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6. 5-year analysis of susceptibilities of Candida and other yeast species to flueonazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol, 2005,43:5848-5859.
  • 7Anunnatsiri S, Chetchotisakd P, Mootsikapun P. Fungemia in non- HIV-infected patients: a five-year review. Int J Infect Dis, 2009, 13:90-96.
  • 8Camps IR. Risk facters for invasive fungal infections in haematopoietic stem cell transplantation. Int Antimicrob Agents, 2008, 32Suppl : S119-123.
  • 9Camps IR. Risk facters for invasive fungal infections in haematopoietic stem cell transplantation [ J ]. Int Antimicrob Agents, 2008, 32 ( Supplz) :S119 - 123.
  • 10Osorio JJ, Roman AR, Torre - Cisneros. Spectrum and risk factors of invasive fungal infection [ J ]. Enferm Infecc Microbiol Clin, 2007, 25 (7) :467 -476.

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部